Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Market Cap	12.08B +8.9%
Revenue (ttm)	6.94B +10.2%
Net Income	964.53M +11.7%
EPS	48.15 +11.7%
Shares Out	n/a
PE Ratio	12.52
Forward PE	n/a
Dividend	1.80 (0.30%)
Ex-Dividend Date	Sep 11, 2026

Volume	4,874
Open	603.00
Previous Close	603.55
Day's Range	598.55 - 604.35
52-Week Range	440.00 - 770.00
Beta	0.40
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, anti-infective, anti-bacterial, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics in the form of tablets, capsules, injectables, dry syrups, sprays, ointments etc. It exports its produc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 1,352
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LINCOLN

Financial Performance

In fiscal year 2026, Lincoln Pharmaceuticals's revenue was 6.71 billion, an increase of 7.67% compared to the previous year's 6.23 billion. Earnings were 878.94 million, an increase of 6.74%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error